Skip to main content
Equibles
REGN logo

REGN · Regeneron Pharmaceuticals, Inc. · Metrics

Track REGN — free

Use REGN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research REGN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$759.00 +8.49 (+1.13%) At close · Sep 30
S&P 500 member Nasdaq-100 member Russell 1000 member Rebalance outlook locked
Market Cap
$81.13B
Shares
102.95M
Volume · Sep 30 873.34K Avg daily vol (3M) 755K

REGN metrics

81 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$750.51
Market cap
$81.13B

Price action

20 metrics
Price change (1W)
-6.6%
Price change (30D)
-6.1%
Price change (3M)
+20.4%
Price change (6M)
-2.9%
Price change (YTD)
-2.8%
Price change (1Y)
+33.8%
Trailing year
Price change (5Y)
+23.7%
52-week high
$852.03
52-week low
$557.73
Change from 52-week high
-11.9%
Change from 52-week low
+34.6%
Annualized volatility
33.3%
Annualized volatility (3M)
31.6%
Beta
0.5
RSI (14D)
37.3
Price vs SMA 50
-3.8%
Price vs SMA 200
+2.0%
Avg volume (3M)
754,998
Relative volume
1.1
Average dollar volume
$566.24M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
102.95M

Valuation

12 metrics
P / E (TTM)
18.6
Trailing earnings · reciprocal yield 5.4%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
5.2×
reciprocal yield 19.1%
P / book
2.6
reciprocal yield 39.1%
FCF yield
4.6%
TTM · current market cap
Buyback yield
4.1%
P / FCF
21.6
reciprocal yield 4.6%
P / operating cash flow
17.3
reciprocal yield 5.8%
Earnings yield
5.3%

Historical valuation

8 metrics
P / E historical average (3Y)
20.4×
reciprocal yield 4.9%
P / E historical average (5Y)
17.7×
reciprocal yield 5.6%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
8.7%
Shareholder yield
4.5%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-10-30
Last earnings
2026-07-30

Profitability

9 metrics
Gross margin
—
Operating margin
24.7%
Trailing 12 months
Net margin
27.9%
Gross profit (TTM)
—
Operating profit (TTM)
$3.84B
Net income (TTM)
$4.33B
Trailing 12 months
Diluted EPS (TTM)
$40.38
FCF margin
24.2%
Effective tax rate
16.2%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$8.54

Growth

11 metrics
Revenue growth YoY
+16.7%
Year over year
Net income growth YoY
-6.8%
Revenue (TTM)
$15.53B
Trailing 12 months
EPS growth YoY
-4.5%
Shares change YoY
-2.4%
Year over year · fewer shares
Revenue CAGR (3Y)
+5.6%
Revenue CAGR (5Y)
+11.0%
EPS CAGR (3Y)
+2.8%
EPS CAGR (5Y)
+6.3%
FCF CAGR (3Y)
-2.7%
FCF CAGR (5Y)
+15.3%

Quality

14 metrics
Return on equity
13.7%
Return on assets
10.4%
Debt / equity
—
Current ratio
3.3
EBITDA (TTM)
$4.37B
Free cash flow (TTM)
$3.76B
Quick ratio
2.8
Interest coverage
69.4
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$2.46B
Total assets
$41.73B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$4.68B
Capital expenditures (TTM)
$920.90M
R&D (TTM)
$6.28B
SG&A (TTM)
$2.74B
Stock compensation (TTM)
$986.70M
R&D / revenue
40.4%
Stock compensation / revenue
6.4%

Ownership (13F)

3 metrics
13F filers
1,347
13F filer change QoQ
-61
Institutional ownership
91.5%

Short interest

3 metrics
Short interest
2.5%
Latest settlement · 4.4 days to cover
Days to cover
4.4d
Short-squeeze score
53 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$3.30M
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 872589 CUSIP 75886F107 13F (30d) 24 filings 20 filers Visit website Investor relations